Pharmaceuticals for left ventricular (LV) dysfunction do not have similar success in right ventricular (RV) failure, which may reflect biological differences between the ventricles. In this study, we performed Ingenuity Pathway Analysis of the Human Cell Atlas to understand how the transcriptomic signatures of the RV and LV differ.
|Original language||English (US)|
|State||Published - Jan 2022|
Bibliographical noteFunding Information:
Sasha Z. Prisco is funded by NIH F32 HL154533, NIH T32 HL144472, a University of Minnesota Clinical and Translational Science award (NIH UL1 TR002494), and a University of Minnesota Medical School Academic Investment Educational Program grant. Thenappan Thenappan is funded by the Cardiovascular Medical Research and Education Fund and the University of Minnesota Futures Grant. Kurt W. Prins is funded by NIH K08 HL140100, the Jenesis Award from United Therapeutics, a Lillehei Heart Institute Cardiovascular Seed Grant, the University of Minnesota Futures Grant, the University of Minnesota Faculty Research Development Grant Program, the Cardiovascular Medical Research and Education Fund, and an American Lung Association Innovative Award IA‐816386. The content is solely the responsibility of the authors and does not represent the official views of the NIH or any other funding sources.
© 2021 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.
- heart diseases
- pulmonary heart disease
- right ventricle function and dysfunction
PubMed: MeSH publication types
- Journal Article